Biostage Inc., (Nasdaq: BSTG), (“Biostage” or the “Company”), a biotechnology company developing bioengineered organ implants to treat cancer, congenital abnormalities and other life-threatening conditions of the esophagus, bronchus and trachea, today announced the use of Biostage’s Cellspan Esophageal Implant product candidate in a patient at a major U.S. hospital via an FDA-approved single-use expanded access application.
http://markets.businessinsider.com/news/stocks/Biostage-Announces-the-Use-of-Its-Esophageal-Implant-Product-Candidate-in-a-Patient-1002236694
Biostage Announces the Use of Its Esophageal Implant Product Candidate in a Patient